PF-06669571

DRUG2 trials

Sponsors

Pfizer

Conditions

HealthyIdiopathic Parkinson's Disease

Phase 1

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

CompletedNCT02184429

Start: 2014-07-31End: 2015-03-31Updated: 2018-09-06

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

CompletedNCT02565628

PfizerIdiopathic Parkinson's Disease

Start: 2015-11-16End: 2016-05-13Updated: 2023-07-24

Related Papers

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.

2018-06-0114 citations